Simplify Logo

Full-Time

Patient Access Liaison

Northeast

Posted on 10/18/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$165k - $220kAnnually

+ Performance Bonus + Equity

Senior

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • BA/BS degree is preferred
  • Minimum of 5-8 years of Biotech/Pharma experience. Patient services, Market Access, and hub experience preferred
  • Cardiology, Pediatric, Oncology, and Rare Disease experience are preferred
  • Strong communication and interpersonal skills
  • Ability to work independently and in a team environment
  • Demonstrate confidence in building rapport with patients/care partners
  • Must have a strong foundation and experience working closely with patient support programs, including copay, cost-sharing programs, affordability design, and hub models for medical and pharmacy benefit products
  • Comprehend the complex environment of the specialty market, buy and bill, retail market, reimbursement/access challenges, as well as the OIG/CMS/legal guidelines for offering patient support programs
  • Demonstrate excellent analytical skills and the ability to develop sound strategies and tactics for patient access
  • Exhibit superior communication (oral and written) and teamwork skills to effectively contribute across cross-functional teams
  • Training experience is a plus
  • Extremely detail-oriented oriented to create and manage program documents
  • Experience establishing and maintaining high-level relationships with key decision-makers
Responsibilities
  • Provide patient/care partner-facing access and affordability support for all BridgeBio Commercialized assets. This requires working closely with the Market Access team, Commercial, Training, and Brand Marketing team
  • Compliantly ensure a positive patient journey through collaborations with all BridgeBio stakeholders
  • Lead the evaluation and implementation of patient access opportunities within a specific geographic area for all applicable patients
  • Provide face-to-face or via phone personalized issue resolution, including potential hurdles with access and affordability with patients/care partners
  • Direct access support between consented patients and all relevant stakeholders (hub, pharmacies, prescriber’s offices, and support organizations)
  • Coordinate with the hub partner on missing information follow-ups
  • Own the relationship between ForgingBridges, a support program offered to patients to access BridgeBio-approved medicines, and consented patients
  • Onboard and welcome new patients to the ForgingBridges support program
  • Manage patient status changes with ForgingBridges and follow up with patients/care partners, prescriber’s offices, and pharmacies
  • Ensure ForgingBridges support program business rules are followed
  • Control the workflow of information and communications with consented patients
  • Collaborate with the BridgeBio Patient Advocacy team on patient/care partner engagements and attend local, regional, and national advocacy meetings/events
  • Facilitate and present in-office education with patients/care partners as requested
  • Report key insights and findings in a compliant manner to the Brand Marketing and other internal Commercial functions
  • Follow BridgeBio’s policy on handling protected health information (PHI) obtained through pharmacies, prescriber’s offices, and interactions with patients/care partners
  • As needed, attend Commercial national sales meetings, conferences, and regional events
  • Work on designated projects that are within the scope of services for Market Access as assigned and/or consistent with developmental plans and strengths
  • Provide strategic and tactical input for continuous improvement purposes
  • Develop tactical plans (i.e., educating, triaging, hub interactions, etc.) and execute against those plans in support of strategic access imperatives, such as key performance indicators or role metrics as identified by Market Access leadership
  • Additional responsibilities may be assigned
  • 80% domestic travel is required, regionally and intermittently across the US

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Unlike many competitors, BridgeBio emphasizes independent thinking and transparency, enabling rapid, data-driven decision-making. The company's goal is to create significant therapeutic advancements by targeting diseases at their genetic source, ultimately bringing effective treatments to market more quickly.

Company Stage

IPO

Total Funding

$6.8B

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

24%

1 year growth

65%

2 year growth

88%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.

Help us improve and share your feedback! Did you find this helpful?